NovoCure Limited (NVCR)
USD 31.54
(-1.73%)
USD 31.54
(-1.73%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 783.63 Million USD | 4.42% |
| 2022 | 750.47 Million USD | 2.95% |
| 2021 | 729 Million USD | 26.68% |
| 2020 | 575.45 Million USD | 119.93% |
| 2019 | 261.65 Million USD | 15.0% |
| 2018 | 227.53 Million USD | 49.96% |
| 2017 | 151.73 Million USD | 8.59% |
| 2016 | 139.73 Million USD | 147.25% |
| 2015 | 56.51 Million USD | 182.57% |
| 2014 | 20 Million USD | 16.75% |
| 2013 | 17.13 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 762.07 Million USD | -2.75% |
| 2024 Q2 | 850.42 Million USD | 11.59% |
| 2024 Q3 | 861.2 Million USD | 1.27% |
| 2023 Q4 | 783.63 Million USD | 4.12% |
| 2023 Q3 | 752.64 Million USD | 1.25% |
| 2023 Q2 | 743.33 Million USD | 0.15% |
| 2023 Q1 | 742.19 Million USD | -1.1% |
| 2023 FY | 783.63 Million USD | 4.42% |
| 2022 Q2 | 721 Million USD | 0.93% |
| 2022 FY | 750.47 Million USD | 2.95% |
| 2022 Q3 | 728.81 Million USD | 1.08% |
| 2022 Q4 | 750.47 Million USD | 2.97% |
| 2022 Q1 | 714.32 Million USD | -2.01% |
| 2021 Q2 | 699.79 Million USD | 0.62% |
| 2021 FY | 729 Million USD | 26.68% |
| 2021 Q3 | 707.28 Million USD | 1.07% |
| 2021 Q4 | 729 Million USD | 3.07% |
| 2021 Q1 | 695.49 Million USD | 20.86% |
| 2020 Q2 | 261.11 Million USD | 0.24% |
| 2020 FY | 575.45 Million USD | 119.93% |
| 2020 Q4 | 575.45 Million USD | 364.03% |
| 2020 Q3 | 124.01 Million USD | -52.51% |
| 2020 Q1 | 260.5 Million USD | -0.44% |
| 2019 Q4 | 261.65 Million USD | 3.22% |
| 2019 FY | 261.65 Million USD | 15.0% |
| 2019 Q3 | 253.49 Million USD | 2.51% |
| 2019 Q2 | 247.28 Million USD | 1.4% |
| 2019 Q1 | 243.86 Million USD | 7.18% |
| 2018 Q4 | 227.53 Million USD | 13.44% |
| 2018 FY | 227.53 Million USD | 49.96% |
| 2018 Q1 | 197.36 Million USD | 30.07% |
| 2018 Q2 | 197.79 Million USD | 0.22% |
| 2018 Q3 | 200.57 Million USD | 1.41% |
| 2017 Q4 | 151.73 Million USD | 4.22% |
| 2017 FY | 151.73 Million USD | 8.59% |
| 2017 Q1 | 135.72 Million USD | -2.87% |
| 2017 Q2 | 139.49 Million USD | 2.78% |
| 2017 Q3 | 145.59 Million USD | 4.37% |
| 2016 FY | 139.73 Million USD | 147.25% |
| 2016 Q4 | 139.73 Million USD | 5.18% |
| 2016 Q3 | 132.85 Million USD | 107.99% |
| 2016 Q2 | 63.87 Million USD | 9.01% |
| 2016 Q1 | 58.59 Million USD | 3.67% |
| 2015 Q2 | 48.46 Million USD | 14.24% |
| 2015 FY | 56.51 Million USD | 182.57% |
| 2015 Q1 | 42.42 Million USD | 112.09% |
| 2015 Q4 | 56.51 Million USD | 7.53% |
| 2015 Q3 | 52.55 Million USD | 8.45% |
| 2014 Q1 | - USD | 0.0% |
| 2014 FY | 20 Million USD | 16.75% |
| 2014 Q4 | 20 Million USD | 0.0% |
| 2013 FY | 17.13 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Akoya Biosciences, Inc. | 126.59 Million USD | -518.988% |
| AngioDynamics, Inc. | 112.08 Million USD | -599.142% |
| AtriCure, Inc. | 147.76 Million USD | -430.327% |
| Avinger, Inc. | 19.97 Million USD | -3823.658% |
| Azenta, Inc. | 351.22 Million USD | -123.117% |
| BioLife Solutions, Inc. | 75.05 Million USD | -944.134% |
| The Cooper Companies, Inc. | 4.1 Billion USD | 80.924% |
| Daxor Corporation | 858.75 Thousand USD | -91151.901% |
| Ekso Bionics Holdings, Inc. | 16.31 Million USD | -4704.028% |
| Femasys Inc. | 9.4 Million USD | -8233.652% |
| GlucoTrack, Inc. | 1.7 Million USD | -45780.152% |
| Harvard Bioscience, Inc. | 64.29 Million USD | -1118.865% |
| Hologic, Inc. | 4.02 Billion USD | 80.536% |
| ICU Medical, Inc. | 2.25 Billion USD | 65.25% |
| Intuitive Surgical, Inc. | 2.04 Billion USD | 61.666% |
| KORU Medical Systems, Inc. | 8.1 Million USD | -9565.888% |
| LeMaitre Vascular, Inc. | 48.87 Million USD | -1503.243% |
| Innovative Eyewear, Inc. | 659.93 Thousand USD | -118643.787% |
| Innovative Eyewear, Inc. | 659.93 Thousand USD | -118643.787% |
| Masimo Corporation | 1.67 Billion USD | 53.263% |
| Microbot Medical Inc. | 3.82 Million USD | -20381.783% |
| Meihua International Medical Technologies Co., Ltd. | 25.07 Million USD | -3024.851% |
| Merit Medical Systems, Inc. | 1.12 Billion USD | 30.235% |
| Nephros, Inc. | 3.5 Million USD | -22270.34% |
| NEXGEL, Inc. | 4.78 Million USD | -16263.186% |
| NEXGEL, Inc. | 4.78 Million USD | -16263.186% |
| Singular Genomics Systems, Inc. | 86.46 Million USD | -806.343% |
| OraSure Technologies, Inc. | 52.17 Million USD | -1401.961% |
| Pro-Dex, Inc. | 23.34 Million USD | -3257.036% |
| Pulse Biosciences, Inc. | 16.44 Million USD | -4665.465% |
| Predictive Oncology Inc. | 6.14 Million USD | -12651.395% |
| Precision Optics Corporation, Inc. | 6.84 Million USD | -11348.612% |
| QuidelOrtho Corporation | 3.55 Billion USD | 77.971% |
| Repligen Corporation | 853.2 Million USD | 8.155% |
| Sanara MedTech Inc. | 29.28 Million USD | -2576.056% |
| STAAR Surgical Company | 102.73 Million USD | -662.749% |
| Sharps Technology, Inc. | 3.85 Million USD | -20227.799% |
| Utah Medical Products, Inc. | 7.14 Million USD | -10867.572% |
| DENTSPLY SIRONA Inc. | 4.07 Billion USD | 80.774% |
| Jin Medical International Ltd. | 8.92 Million USD | -8680.846% |